Reunion Neuroscience Inc. announced that it has appointed psychiatrist Fred Grossman, and medical affairs, pharmacovigilance and health outcomes across a variety of products, including biologics and small molecules. Dr. Grossman previously served as the Chief Medical Officer at Empyrean Neuroscience, Mesoblast Limited and NeuroRx Pharma and has held senior executive leadership positions at Glenmark Pharmaceuticals, Sunovion Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson and Eli Lilly, Dr. Grossman is a Board-Certified Psychiatrist and Fellow of the American Psychiatric Association. He has authored numerous scientific publications and has held academic appointments at several universities.

He completed his residency in psychiatry at Hahnemann University and a pharmacology fellowship at the National Institutes of Health (NIH).